PersonalisPSNL
PSNL
About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Employees: 225
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
329% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]
89% more capital invested
Capital invested by funds: $158M [Q3] → $298M (+$141M) [Q4]
25% more funds holding
Funds holding: 83 [Q3] → 104 (+21) [Q4]
17.52% more ownership
Funds ownership: 55.11% [Q3] → 72.63% (+17.52%) [Q4]
6% less call options, than puts
Call options by funds: $482K | Put options by funds: $511K
29% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 34
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7.25
54%
upside
Avg. target
$8.08
72%
upside
High target
$9
91%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 38% 1-year accuracy 74 / 194 met price target | 70%upside $8 | Buy Maintained | 27 Jan 2025 |
Lake Street Thomas Flaten 25% 1-year accuracy 3 / 12 met price target | 91%upside $9 | Buy Maintained | 8 Jan 2025 |
Needham Mike Matson 55% 1-year accuracy 67 / 122 met price target | 54%upside $7.25 | Buy Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 6 articles about PSNL published over the past 30 days
Positive
Seeking Alpha
15 hours ago
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Negative
Zacks Investment Research
1 day ago
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
3 days ago
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025, at the Boston Marriott Copley Place in Boston, MA. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guidi.
Positive
Seeking Alpha
1 week ago
Exciting Technology At Personalis, But Profitability Eludes Them
Personalis specializes in ultrasensitive cancer detection technology, with promising products like NeXT Personal and ImmunoID NeXT, but faces profitability challenges. The company has strong financials with a good cash position and no debt, but struggles with test reimbursement impacting gross margins. Partnerships with Tempus AI and Merck provide capital and credibility, but profitability is projected to be years away, possibly until 2029.
Neutral
Business Wire
1 week ago
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 fo.
Neutral
Business Wire
3 weeks ago
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 11, 2025, at The Cliff Lodge in Snowbird, UT. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm.
Positive
Zacks Investment Research
1 month ago
Personalis (PSNL) Upgraded to Buy: Here's Why
Personalis (PSNL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Business Wire
1 month ago
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London's Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight advancements in lung cancer detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect.
Neutral
Business Wire
1 month ago
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance. Preliminary Full Year 2024 Revenue Revenue of approximately $84.6 million for the full year of 2024 compared with $73.5 million for the full year of 2023, an increase of 15%, and above the company's previous full year guidance range of $83.0.
Neutral
Business Wire
2 months ago
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company's business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis' ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen.
Charts implemented using Lightweight Charts™